The shareholders have voted overwhelmingly to remove ITL Health Group Limited from the official list of the ASX at the Extraordinary General Meeting held today at 10:00 am.
ITL Health Group Limited (‘ITL’) has today, following a resolution of the Board of Directors, submitted a formal application for the removal of ITL’s fully paid ordinary shares (‘Shares’) from the Official List of Australian Securities Exchange (‘ASX’) pursuant to ASX Listing Rule 17.11.
ITL Health Group (ASX:ITD), a manufacturer and seller of medical technology to the global blood industry and developer of innovative direct-to-consumer pathology testing services, announces results for the year ended 30 June 2018.
ITL Health Group (ASX:ITD) is pleased to announce the launch of ITL BioMedical’s latest innovative product to support the microbiology laboratory blood culture testing process. The Safety SubCulture Units 2 (SCU2) is one of a pipeline of new products to be brought to market in the current financial year.
ITL Health Group (ASX:ITD) is pleased to announce the launch of ITL BioMedical’s latest pre-analytical products for blood culture sample collection, SampLok® Adapter Cap 2 and SampLok® Adapter Cap 3.
ITL Health Group (“ITL”), a manufacturer and seller of medical technology to the global blood market and consumer pathology test provider, is pleased to announce results for the half year ended 31 December 2017.
ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has launched a prostate specific antigen (PSA) test service to help men who wish to monitor their PSA level from home. The test means MHT is now marketing four test services to total addressable markets in excess of $1bn.